Navigation Links
Chiltern Announces The Consolidation Of Existing Investor Base

LONDON and WILMINGTON, N.C., Dec. 17, 2013 /PRNewswire/ -- Chiltern International Limited ("Chiltern" or "the Company"), a global contract research organization (CRO), announces the consolidation of the ownership of existing investors, led by interests associated with Sir Douglas Myers. This consolidated investor base enables Chiltern to continue to deliver on its strategic plan for growth while maintaining its focus on the delivery of high quality, innovative clinical trial services and therapeutic expertise.

The new ownership structure offers greater access to new investment to further the development of Chiltern. It will provide Chiltern with the means to expand further and develop within key target markets, both organically and through investment in people, technology and client relationships, as well as external opportunities to optimize Chiltern's mid-tier leadership position through carefully targeted acquisitions.

Demand for Chiltern's services is at an all-time high: the Company announced a record financial performance in the year ended March 2013, with top line growth of 16.8% to £104m, taking the five year revenue CAGR to 15.3% for 2008-2013. The new investment will allow Chiltern to maintain this substantial growth and to continue to drive the Company forward.

The global CRO market is expected to show continued growth as the pharmaceutical industry responds to significant sector challenges. These include the growing pressure to increase R&D productivity, the rising cost and complexity of clinical trials, increasing regulatory hurdles, and a desire to shift fixed to variable cost. These industry drivers represent a significant opportunity for Chiltern.

Nick Thornton, Chairman of Chiltern, said: "This new investment is a significant milestone in Chiltern's history. For over 30 years, Chiltern's success has been underpinned by a tradition of ownership led by private investment. We have continued to grow our market share as our customers have increasingly sought mid-tier global CROs with the ability to deliver better value and a comprehensive range of high quality services."

Jim Esinhart, CEO of Chiltern, said: "This investment will allow us to continue to invest in organic growth and explore external acquisition opportunities. I am excited to be leading Chiltern to the next phase of growth. Our mission has not changed – we are committed and will continue to deliver expert, high quality, clinical development services around the world whilst building trustworthy and lasting relationships, understanding each customer's specific needs and, overall, improving the quality of life."

Company profile:About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. For further information: For more information contact: Natalie ChongSusan OjanenMarketing DirectorMarketing ExecutiveChiltern International Ltd.Chiltern International Inc.171 Bath Road1241 Volunteer ParkwaySloughSuite 950Berkshire SL1 4AABristol, TN 37620UNITED KINGDOMUSATel:  +44 (0) 1753 512Tel:  +1 (423) 968 9533Email: natalie.chong@chiltern.comEmail: susan.ojanen@chiltern.comFor financial enquiries contact: John DineenBen AtwellSenior DirectorSenior Managing DirectorFTI Consulting FTI ConsultingHolborn GateHolborn Gate 26 Southampton Buildings26 Southampton BuildingsLondon WC2A 1PBLondon WC2A 1PBUNITED KINGDOMUNITED KINGDOMTel: +44 (0) 20 7269 7193 directTel: +44 (0) 20 7269 7242 directFax: +44 (0) 203 077 0519Fax: +44 (0) 203 077 0519 Email: John.Dineen@fticonsulting.comEmail:

SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cynosure Announces Successful Settlement of Patent Infringement Lawsuits Against Tria Beauty
2. Zimmer Announces Fourth Quarter Dividend and New Share Repurchase Program
3. Varian Imaging Components President Robert Kluge Announces Plans to Retire; Varian CEO Dow Wilson Names Sunny Sanyal as Kluges Successor
4. Medical Tracking Solutions, Inc. announces new client Custom Spine, Inc.
5. Avista Capital Partners Announces a Majority Investment in Vertical Pharmaceuticals and Trigen Laboratories
6. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
7. Amgen Announces 2014 First Quarter Dividend
8. BioSpecifics Technologies Corp. Announces Initiation of Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome
9. Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roches latest targeted medicines, Perjeta and Kadcyla
10. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
11. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
Post Your Comments:
(Date:5/30/2020)... (PRWEB) , ... May 29, 2020 , ... ... following statement in response to the U.S. announcement that it will terminate its ... the Administration’s announcement that it plans to terminate its relationship with the World ...
(Date:5/30/2020)... ... May 30, 2020 , ... Pregnancy is stressful already, ... issues related to COVID-19. Recently, Wellness Expert Jamie Hess teamed with One A ... pregnancy and postpartum. , A video accompanying this announcement is available at: ...
(Date:5/28/2020)... ... May 28, 2020 , ... May is Talking is Power Month, a national ... care about them. The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted ... Power to Decide’s Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... In ... will be lifted on May 28th and all businesses will be required to ... returning back to work. , As an essential business, AmeriCare Medical began this ...
(Date:5/21/2020)... ... May 21, 2020 , ... The Rise of Mental Health and Substance Abuse ... complications and adjustments, needless to say, more complications. With rising deaths, more confirmed cases ... it can be hard to escape and find peace. Adding to these persistent stressors ...
(Date:5/21/2020)... , ... May 21, 2020 , ... A new ... Medicine Group, details over 90 companies involved in the point of care test industry. ... facilities for preliminary testing, COVID-19 has made point-of-care more important than in the past, ...
(Date:5/17/2020)... , ... May 18, 2020 , ... ... cell therapy program at its Tijuana regenerative clinic. There are two program options ... and safe cell counts. , While it is unclear exactly what causes Autism ...
(Date:5/16/2020)... ... May 15, 2020 , ... On May 21, T1V will host a webinar featuring Dr. ... USC, and a contributor to CBS news, as we address COVID-19 and the impact on ... parts of the country since March, many questions are left unanswered as we look at ...
Breaking Medicine News(10 mins):